Evidence map›Paper›PMID 33008892›Full record

ArticleScience advances2020

The Huntingtin-interacting protein SETD2/HYPB is an actin lysine methyltransferase.

Riyad N H Seervai, Rahul K Jangid, Menuka Karki, Durga Nand Tripathi, Sung Yun Jung, Sarah E Kearns, Kristen J Verhey, Michael A Cianfrocco, Bryan A Millis, Matthew J Tyska and 5 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Ribosome Homeostasis Regulated by SETD2 Preserves Intestinal Epithelial Barrier.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Chromatin modifiers in neurodevelopment.Frontiers in molecular neuroscience · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Riyad N H SeervaiDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA. riyad.seervai@bcm.edu cheryl.walker@bcm.edu ipark@bcm.edu dere@bcm.edu.ORCID 0000-0001-7210-8350
Rahul K JangidCenter for Precision Environmental Health, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0003-0236-9226
Menuka KarkiCenter for Precision Environmental Health, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0002-1234-0024
Durga Nand TripathiDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0001-8736-4808
Sung Yun JungVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0003-1521-7977
Sarah E KearnsDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.ORCID 0000-0001-5640-909X
Kristen J VerheyDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Michael A CianfroccoLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-2067-4999
Bryan A MillisDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.ORCID 0000-0002-5770-627X
Matthew J TyskaDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.ORCID 0000-0003-2238-6189
Frank M MasonVanderbilt-Ingram Cancer Center, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0003-1338-494X
W Kimryn RathmellVanderbilt-Ingram Cancer Center, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0002-4984-0225
In Young ParkCenter for Precision Environmental Health, Baylor College of Medicine, Houston, TX 77030, USA. riyad.seervai@bcm.edu cheryl.walker@bcm.edu ipark@bcm.edu dere@bcm.edu.ORCID 0000-0002-0082-1189
Ruhee DereCenter for Precision Environmental Health, Baylor College of Medicine, Houston, TX 77030, USA. riyad.seervai@bcm.edu cheryl.walker@bcm.edu ipark@bcm.edu dere@bcm.edu.ORCID 0000-0002-1457-609X
Cheryl Lyn WalkerDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA. riyad.seervai@bcm.edu cheryl.walker@bcm.edu ipark@bcm.edu dere@bcm.edu.ORCID 0000-0002-4233-3247
Baylor College of Medicine · USUniversity of Michigan · USVanderbilt University · USVanderbilt University Medical Center · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Translational Research Support CoreP30ES030285 · NIEHS · BAYLOR COLLEGE OF MEDICINE · PI Casey W Wright · 2019 to 2026
$14.7M
Kinesin Motors and Microtubule-based TraffickingR35GM131744 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kristen J. Verhey · 2019 to 2026
$6.3M
A New Target for Chromatin Remodeler Defects in CancerR35CA231993 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WALKER, CHERYL L. · 2018 to 2024
$6.2M
Molecular basis of brush border assemblyR01DK095811 · NIDDK · VANDERBILT UNIVERSITY · PI MATTHEW J TYSKA · 2013 to 2026
$4.9M
Role of I-BAR proteins in enterocyte differentiationR01DK111949 · NIDDK · VANDERBILT UNIVERSITY · PI MATTHEW J TYSKA · 2017 to 2026
$4.2M
TARGETED GENOMICS FACILITY COREP30ES023512 · NIEHS · TEXAS A&M AGRILIFE RESEARCH · PI THREADGILL, DAVID W. · 2014 to 2017
$3.3M
Methyltransferase Contributions to Genomic Stability and CancerR01CA203012 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RATHMELL, WENDY KIMRYN, WALKER, CHERYL L. · 2016 to 2020
$2.2M
BD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430k
NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA203012NCI NIH HHS R35 CA231993NCRR NIH HHS S10 RR024574NIEHS NIH HHS P30 ES023512NIGMS NIH HHS R35 GM131744
6 · The paper itself

Abstract

The methyltransferase SET domain-containing 2 (SETD2) was originally identified as Huntingtin (HTT) yeast partner B. However, a SETD2 function associated with the HTT scaffolding protein has not been elucidated, and no linkage between HTT and methylation has yet been uncovered. Here, we show that SETD2 is an actin methyltransferase that trimethylates lysine-68 (ActK68me3) in cells via its interaction with HTT and the actin-binding adapter HIP1R. ActK68me3 localizes primarily to the insoluble F-actin cytoskeleton in cells and regulates actin polymerization/depolymerization dynamics. Disruption of the SETD2-HTT-HIP1R axis inhibits actin methylation, causes defects in actin polymerization, and impairs cell migration. Together, these data identify SETD2 as a previously unknown HTT effector regulating methylation and polymerization of actin filaments and provide new avenues for understanding how defects in SETD2 and HTT drive disease via aberrant cytoskeletal methylation.

Indexed as

ActinsLysineCytoskeletonGTP-Binding ProteinsHistone-Lysine N-MethyltransferaseMethylationProtein Processing, Post-TranslationalActinsGTP-Binding ProteinsHistone-Lysine N-MethyltransferaseLysine

Identifiers

PMID33008892
PMCPMC7852384
OpenAlexW3090055299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.